Cell Reports (Sep 2015)

ABCB5 Identifies Immunoregulatory Dermal Cells

  • Tobias Schatton,
  • Jun Yang,
  • Sonja Kleffel,
  • Mayuko Uehara,
  • Steven R. Barthel,
  • Christoph Schlapbach,
  • Qian Zhan,
  • Stephen Dudeney,
  • Hansgeorg Mueller,
  • Nayoung Lee,
  • Juliane C. de Vries,
  • Barbara Meier,
  • Seppe Vander Beken,
  • Mark A. Kluth,
  • Christoph Ganss,
  • Arlene H. Sharpe,
  • Ana Maria Waaga-Gasser,
  • Mohamed H. Sayegh,
  • Reza Abdi,
  • Karin Scharffetter-Kochanek,
  • George F. Murphy,
  • Thomas S. Kupper,
  • Natasha Y. Frank,
  • Markus H. Frank

DOI
https://doi.org/10.1016/j.celrep.2015.08.010
Journal volume & issue
Vol. 12, no. 10
pp. 1564 – 1574

Abstract

Read online

Cell-based strategies represent a new frontier in the treatment of immune-mediated disorders. However, the paucity of markers for isolation of molecularly defined immunomodulatory cell populations poses a barrier to this field. Here, we show that ATP-binding cassette member B5 (ABCB5) identifies dermal immunoregulatory cells (DIRCs) capable of exerting therapeutic immunoregulatory functions through engagement of programmed cell death 1 (PD-1). Purified Abcb5+ DIRCs suppressed T cell proliferation, evaded immune rejection, homed to recipient immune tissues, and induced Tregs in vivo. In fully major-histocompatibility-complex-mismatched cardiac allotransplantation models, allogeneic DIRCs significantly prolonged allograft survival. Blockade of DIRC-expressed PD-1 reversed the inhibitory effects of DIRCs on T cell activation, inhibited DIRC-dependent Treg induction, and attenuated DIRC-induced prolongation of cardiac allograft survival, indicating that DIRC immunoregulatory function is mediated, at least in part, through PD-1. Our results identify ABCB5+ DIRCs as a distinct immunoregulatory cell population and suggest promising roles of this expandable cell subset in cellular immunotherapy.